Biotec Pharmacon ASA appoints Dr. Jethro Holter as CEO

(Tromsø 22. April 2020) Biotec Pharmacon ASA (OSE: “BIOTEC”) announced today that its Board of Directors has unanimously appointed Dr Jethro Holter as the Company’s permanent Chief Executive Officer. Dr Holter has been the interim CEO for the last 6 months

Jethro joined ArcticZymes as Managing Director in January 2015. He focused on driving a  new strategic direction channelling the subsidiary’s efforts towards growth, through expanding its B2B client base and implementing a customer-driven innovation approach for new product development. Consequently, the subsidiary has experienced strong revenue growth and vastly expanded its portfolio of novel enzyme products. Today, ArcticZymes is profitable and a leading commercial supplier of enzymes to the molecular biology, In Vitro Diagnostics (IVD) and gene therapy market segments. During his time as interim CEO, Jethro has implemented a new Group strategy and continued to drive healthy growth in the business.

“The Board of Directors is pleased to announce Jethro Holter as the CEO for Biotec Pharmacon ASA going forward. After being hired as the interim CEO 6 months ago, the Board is confident he has the necessary skills and background required to drive the company into profitability and long-term value creation.”, says Chairman of the Board Dr Marie Roskrow

“I am delighted in being appointed CEO. It is an exciting time to lead this company which is in a transition phase with a fresh and inspiring strategic direction. With the talented team behind me, I am confident we can aspire to maximise growth and transform the company into becoming Europe’s leading one-stop-shop for enzymes. As the newly appointed CEO, my first priority will be to drive the company into profitability.”, says CEO Jethro Holter

The Company will present its Q1 2020 results tomorrow morning at 0830

For further information, please contact: